A phase II study of doxorubicin/paclitaxel plus G-CSF for metastatic breast cancer

ONCOLOGY

Volumn 11, Issue 4 SUPPL. 3, 1997, Pages 24-29

  Schwartsmann, Gilberto ^a   Mans, Denis Ricardo ^a   Menke, Carlos Henrique ^a   Xavier, Nilton ^a   Caleffi, Maira ^b   Fabiano, Antonio ^c   Filho, Ferreira ^c   Schunemann, Hugo ^c   Kalakun, Luciane ^c   Koya, Richard ^a   Pohlman, Paula ^a   Venegas, Luiz Fernando ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b Hospital Materno Infantil Presidente Vargas   (Brazil)

^c S Amer Off Anticancer Drug Devmt   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ADULT; AGED; ALOPECIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; METASTASIS; MUCOSA INFLAMMATION; PHASE 2 CLINICAL TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; NEUTROPENIA; PACLITAXEL; SURVIVAL;

EID: 8544236208     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (16)

1. Henderson IC: Breast Diseases, 2nd ed. pp 604-665, Philadelphia. Lippincott, 1991.
2. McVie JG, Schwartsmann G: Oxford Textbook of Oncology, pp 513-523. New York, Oxford University Press, 1995.
3. Schwartsmann G, Pinedo HM: Clinical trials in advanced breast cancer. Eur J Cancer 23:595-597, 1987.
4. Osborne CK. Manual of Oncologic Therapeutics 1989/1990, pp 201-211. Philadelphia. Lippincott, 1989.
5. Seidman AD: The emerging role of paclitaxel in breast cancer therapy. Clin Cancer Res 1:247-256, 1995.
6. Seidman AD, Tiersten A, Hudis C, et al: Phase II trial of pachtaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 13:2575-2581, 1995.
7. Koechli OR, Sevin BU, Perras JP, et al: Characteristics of the combination paclitaxel plus doxorubicin in breast cancer cell lines analyzed with ATP-cell viability assay. Breast Cancer Res Treat 28:21-27, 1993.
8. Arbuck SA: Paclitaxel: What schedule? What dose? J Clin Oncol 12:233-235, 1994.
9. Schwartsmann G, Menke CH, Caleffi M, et al: Phase II trial of Taxol, doxorubicin plus G-CSF in patients with metastatic breast cancer (abstract). Proc Am Soc Clin Oncol 15:126, 1996.
10. Schwartsmann G, Wanders J, Koier I, et al: EORTC New Drug Development Coordinating Committee guidelines for the performance of phase I and II clinical trials. Eur J Cancer 9:1162-1168, 1991.
11. Gianni L, Munzone E, Capri G, et al: Paclitaxel in metastatic breast cancer: A trial of two doses by 3-hour infusion in patients who failed prior therapy with anthracyclines. J Natl Cancer Inst 87:1169-1175, 1995.
12. Sledge GW Jr, Robert N, Sparano JA, et al: Paclitaxel/doxorubicin combinations in advanced breast cancer: The Eastern Cooperative Oncology Group experience. Semin Oncol 21(suppl 8):15-18, 1994.
13. Rowinsky EK, McGuire WP, Guarnieri T, et al: Cardiac disturbances during the administration of Taxol. J Clin Oncol 9:1704-1712, 1991.
14. Gianni L, Munzone E, Capri G, et al: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastalic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688-2699, 1996.
15. Gianni L, Kearns CM, Gianni A, et al: Nonlinear pharmacokinetics and metabolism of pachtaxel and its pharmacokinetic/pharmacodynamic relationships in humans J Clin Oncol 13:180-190, 1995.
16. Berg SL, Cowan KH, Balls FM, et al: Pharmacokinetics of Taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion. J Natl Cancer Inst 86 143-145, 1994.